Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACEi/ARB alone versus ACEi/ARB plus steroids for primary IgA nephropathy
ChiCTR-TRC-06000004Phase 4Completed
- Sponsor
- Peking University First Hospital
- Start
- Jan 2006
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of prednisone, cilazapril and losartan in IgA nephropathy (IgAN) (2 arms), sponsored by Peking University First Hospital. Primary endpoints: 24-hour urinary protein excretion and serum creatinine. Started Jan 2006; status: completed.
02
Drugs
prednisonecilazaprillosartan
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on ChiCTR-TRC-06000004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-06000004.